Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Zgoda na udział w badaniu
- •Rak prostaty z przerzutami w mniej niż 10 miejscach poza głową
- •Pacjent otrzymuje leczenie systemowe od ponad 3 miesięcy
- •Wszystkie ogniska choroby nadają się do leczenia SBRT
✗ Disqualifies
- •Ucisk na rdzeń kręgowy
- •Przeciwwskazania do radioterapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 7, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Princess Margaret Cancer Center
Toronto, Canada
Trial contact
Rachel Glicksman, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.